|
PAPD7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.42660003202388E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.09749997978525E-09 |
| Normal-vs-Stage2 |
5.73739999999434E-05 |
| Normal-vs-Stage3 |
2.29499996784455E-09 |
| Normal-vs-Stage4 |
3.759300E-04 |
| Stage1-vs-Stage2 |
8.099600E-01 |
| Stage1-vs-Stage3 |
3.137400E-01 |
| Stage1-vs-Stage4 |
5.800400E-01 |
| Stage2-vs-Stage3 |
6.798200E-01 |
| Stage2-vs-Stage4 |
6.007800E-01 |
| Stage3-vs-Stage4 |
2.810400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.3303995379016E-10 |
| Normal-vs-AfricanAmerican |
5.402300E-04 |
| Normal-vs-Asian |
1.563930E-02 |
| Caucasian-vs-AfricanAmerican |
7.581200E-01 |
| Caucasian-vs-Asian |
2.466300E-02 |
| AfricanAmerican-vs-Asian |
2.632800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.57169999962059E-07 |
| Normal-vs-Female |
1.27929999926835E-10 |
| Male-vs-Female |
3.267000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.16600000052725E-08 |
| Normal-vs-Age(41-60Yrs) |
3.92150001360392E-09 |
| Normal-vs-Age(61-80Yrs) |
3.1164000269257E-09 |
| Normal-vs-Age(81-100Yrs) |
2.581500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.011400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.236000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.365000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.142600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.069600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.015600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.79312999999404E-05 |
| Classical-VS-Follicular |
1.79853999999757E-05 |
| Classical-VS-Other |
7.637600E-01 |
| Classical-VS-Normal |
2.03309999999846E-05 |
| Tall-VS-Follicular |
4.306200E-01 |
| Tall-VS-Other |
8.781900E-02 |
| Tall-VS-Normal |
1.02330033335818E-10 |
| Follicular-VS-Other |
2.937600E-01 |
| Follicular-VS-Normal |
2.2027002444247E-10 |
| Other-VS-Normal |
3.281900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.01120248127995E-11 |
| Normal-vs-N1 |
4.176200E-04 |
| N0-vs-N1 |
1.157180E-01 |
|
|
